Melanoma Coverage from Every Angle
Editors:
Daniel G. Coit, MD
Michael A. Postow, MD
Advertisement
Advertisement

Ongoing CE Activities

A 3D Tour of Immuno-Oncology: Melanoma
Adding Oncolytic Virus to Immunotherapy for Advanced Melanoma is Found to be Cost Prohibitive
Advances In™: Metastatic Melanoma: Current Role and Future Potential of Oncolytic Viral Therapy
BRAF/MEK Inhibitor Combo Produces Benefits in Advanced Melanoma
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Community Practice Connections™: Melanoma Tumor Board: Matching Treatment to Patient
Community Practice Connections™: Optimizing Outcomes in Melanoma with BRAF/MEK Inhibitor and Immunotherapeutic Strategies: Essentials for the Onco-Nurse
Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes
First-Line Immune Tx: An Option in V600K-Mutant Melanoma
From IDO to IDON'T: Lessons Learned After a Combo Fails in Advanced Melanoma
Insights & Updates in the Multidisciplinary Treatment of Metastatic Melanoma
Is Mohs Surgery Better Than Traditional Excision for Early-Stage Melanoma?
Monthly Oncology Tumor Boards : A Multidisciplinary Approach To Individualized Patient Care
Multi-Modality Management of Stage IV Melanoma in the Era of Immunotherapy
NCCN Guidelines Insights - Uveal Melanoma Version 1.2019
Oncology Briefings™: How Can Nurses Make the Biggest Impact in Melanoma Treatment and Management?
Oncology Today with Dr. Neil Love, Melanoma Edition: Case Study
Oncology Today with Dr. Neil Love, Melanoma Edition: Evolving Adjuvant Treatment Approaches for Patients With Localized Melanoma
Pearls for Screening and Management of Cutaneous Malignancies
Proceedings from the First Annual Oncology Nursing Retreat
Targeting BRAF/MEK in Melanoma Raises CV Risks
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved